Onkologie. 2014:8(4):163-166

Colorectal cancer in the elderly

Lenka Ostřížková
Interní, hematologická a onkologická klinika FN Brno

The population in the Czech Republic is ageing and the life expectancy is extending. The number of patients with colorectal cancer in

this age group has been constantly increasing. What are the options for treating colorectal cancer in the elderly?

Keywords: population ageing, colorectal cancer, chemotherapy and targeted therapy in the elderly

Published: October 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ostřížková L. Colorectal cancer in the elderly. Onkologie. 2014;8(4):163-166.
Download citation

References

  1. Seymour MT, Thompson LC, Wasan HS, et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet. 2011; 377: 1749-1759. Go to original source... Go to PubMed...
  2. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007; 25: 1658-1664. Go to original source... Go to PubMed...
  3. Bouchahda M, Macarulla T, Spano JP, et al. Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer. Crit Rev Oncol Hematol. 2008; 67: 255-262. Go to original source... Go to PubMed...
  4. Cassidy J, Saltz LB, Giantonio BJ, et al. Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. J Cancer Res Clin Oncol. 2010; 136: 737-748. Go to original source... Go to PubMed...
  5. Kozloff MF, Berlin J, Flynn PJ, et al. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study. Oncology. 2010; 78: 329-339. Go to original source... Go to PubMed...
  6. Ong ES, Alassas M, Dunn KB, Rajput A. Colorectal cancer surgery in the elderly: acceptable morbidity? Am J Surg. 2008; 195: 344-348. Go to original source... Go to PubMed...
  7. Schiffmann L, Ozcan S, Schwarz F, et al. Colorectal cancer in the elderly: surgical treatment and long-term survival. Int J Colorectal Dis. 2008; 23: 601-610. Go to original source... Go to PubMed...
  8. Fong Y, Blumgart LH, Fortner JG, Brennan MF. Pancreatic or liver resection for malignancy is safe and effective for the elderly. Ann Surg. 1995; 222: 426-434. Go to original source... Go to PubMed...
  9. Cunnigham et al, AVEX bevacizumab and capecitabin in 1.line therapy mCRC in elderly patients ASCO GI 2013 abstract 337. Go to original source...
  10. Adam R, Frilling A, Elias D, et al. Liver resection of colorectal metastases in elderly patients. Br J Surg. 2010; 97: 366-376. Go to original source... Go to PubMed...
  11. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001; 345: 1091-1097. Go to original source... Go to PubMed...
  12. Jackson McCleary NA, Meyerhardt J, Green E, et al. Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients (pts) with stage II/III colon cancer: findings from the ACCENT Database [abstract] J Clin Oncol. 2009; 27(Suppl 15): Abstract 4010. Go to original source... Go to PubMed...
  13. Folprecht G, Cunningham D, Ross P, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol. 2004; 15: 1330-1338. Go to original source... Go to PubMed...
  14. Figer A, Perez-Staub N, Carola E, et al. FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study. Cancer. 2007;110:2666-2671. Go to original source... Go to PubMed...
  15. Cunnigham, et al. AVEX bevacizumab and capecitabin in 1.line therapy mCRC in elderly patients ASCO GI 2013 abstract 337. Go to original source...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.